ARVINAS INC (ARVN)
Health Care · NASDAQ
Arvinas is a clinical-stage biopharmaceutical company developing PROTAC protein degraders, a targeted protein degradation platform designed to degrade or destroy disease-causing proteins inside cells.
What ARVINAS INC does
Arvinas is a clinical-stage biopharmaceutical company developing PROTAC protein degraders, a targeted protein degradation platform designed to degrade or destroy disease-causing proteins inside cells. The company is advancing multiple clinical candidates including ARV-102 for neurodegenerative diseases, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for lymphoma, and ARV-027 for polyQ-AR disorders. Arvinas also has collaborations with Pfizer on vepdegestrant for breast cancer and with Novartis on luxdegalutamide for obesity.
Themes: ["targeted protein degradation / PROTACs","LRRK2 / Parkinson's disease and progressive supranuclear palsy","KRAS G12D oncology","BCL6 / non-Hodgkin lymphoma","neurodegenerative disease","undruggable protein targets","polyQ-AR / neuromuscular","obesity / GLP-1","ER+ breast cancer"]
Fundamentals
- Price$8.54 as of 2026-07-09 close
- Market cap$553M as of 2026-07-10
- 1-year return+6.7% as of 2026-07-09 close
- Net margin-247.5% as of 2026-07-10
- ROE-44.4% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-79.1% as of 2026-07-10
- Revenue CAGR (3y)+26.0% SEC XBRL
- Beta1.73 as of 2026-07-10
Key risks (from latest filing)
["Company has generated no product sales revenue to date and expects to incur significant operating losses for at least several more years; accumulated deficit of $1.6 billion as of end of 2025.","Multiple clinical programs face regulatory and development uncertainties; ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant are still in clinical trials with no approved products yet.","Dependence on collaborations (Pfizer for vepdegestrant, Novartis for luxdegalutamide) and third-party partners for manufacturing and commercialization creates execution risk and reduces control of product success."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.